Alexandra Bussopulos

Learn More
OBJECTIVE The ACCESS trial examined the 12-month effectiveness of continuous therapeutic assertive community treatment (ACT) as part of integrated care compared to standard care in a catchment area comparison design in patients with schizophrenia spectrum disorders treated with quetiapine immediate release. METHOD Two catchment areas in Hamburg, Germany,(More)
We report on a patient with genetically proven Machado-Joseph Disease (MJD) presenting with signs indistinguishable from Parkinson's disease (PD), including levodopa response and typical levodopa-induced motor fluctuations. Only after 10 years of prolonged benefit from levodopa and different dopamine agonists (DA), the patient developed cerebellar ataxia(More)
OBJECTIVE Since the beginning of the integrated care model for severely ill patients with psychotic disorders ("Hamburg model") in 2007 different clinical parameters have been consecutively assessed within a naturalistic, observational, prospective study. METHODS Clinical outcome of the 2-year and 4-year follow-ups of n = 158 patients. RESULTS A(More)
OBJECTIVE The "Hamburg model" designates an integrated care model for severely ill patients with psychotic disorders financed by the health insurance system in accordance with § 140 SGB V. METHODS It comprises comprehensive and long-term treatment within a regional network of the psychosis center of the University Medical Center Hamburg-Eppendorf (UKE)(More)
OBJECTIVE The ACCESS treatment model offers assertive community treatment embedded in an integrated care program to patients with psychoses. Compared to standard care and within a controlled study, it proved to be more effective in terms of service disengagement and illness outcomes in patients with schizophrenia spectrum disorders over 12 months. ACCESS(More)
Objective A growing body of research indicates that a low subjective well-being (SW) may be predictive of non-adherence and less favourable outcome. This study examined baseline variables and variables in the course of treatment hypothesised to be associated with later SW. Methods Sixty-three inpatients with schizophreniform disorder or schizophrenia were(More)
Lassen sich muskuläre Gesichtsschmerzen durch die Gabe von Botulinumtoxin A (BTX A) günstig beeinflussen? Bei 20 Patienten mit persistierenden muskulären Gesichtsschmerzen wurden nach Injektion von 25–50 U Dysport® in den/die betreffenden Muskel(n) in 2-Wochen-Intervallen über einen Zeitraum von 8 Wochen eine Befragung und Untersuchung durchgeführt. Der(More)
OBJECTIVE Can chronic pain of the masticatory muscles be positively affected by low dose injection of botulinum toxin (BTX-A)? METHODS Twenty patients suffering chronic myofacial pain were questioned and examined after injection of 25-50 U Dysport into the affected muscles over a period of 8 weeks. RESULTS Four weeks after injection of BTX-A patients(More)
  • 1